No Data
No Data
Everest Medicines Grants Options, Awards Under Employees Incentive Schemes
Genting New Star - B (01952.HK) granted 0.24 million share options and 0.498 million incentive shares.
Great Wall News October 2nd | Genting New Shine-B (01952.HK) announced that on October 2, 2024, the board of directors (i) granted a total of 0.24 million share options in accordance with the rights issue after the initial public offering; and (ii) granted a total of 0.498 million incentives under the employee share option scheme before the initial public offering.
EVEREST MED-B: 2024 Interim Report
Hong Kong stocks soared in the afternoon. Genting New Vision-B (01952) rose more than 5%, while E Jiahe's sales of Nai Fuke soared significantly, with product sales in the first half of the year increasing by more than 1.5 times compared to the previous p
Yunding Xinyao-B (01952) rose more than 5% in the afternoon, as of the time of writing, up 5.80%, at HKD 21.9, with a turnover of HKD 67.6309 million.
Analysts Have Made A Financial Statement On Everest Medicines Limited's (HKG:1952) Half-Yearly Report
[Brokerage Focus] Bocom Intl raises target price by 7.32% for Genting New York (01952) as YiJiaHe and NaiFuKang sales volume significantly exceeds expectations.
Kingwu Financial News | Bocom Intl released its research report, indicating that the sales performance of Cloud Glory New Shine (01952) in 1H24 was excellent: product sales increased by 158% to 0.302 billion yuan compared to the previous period, exceeding market expectations. This includes: 1) After Nafucan was commercialized in mainland China in May, sales reached 0.167 billion yuan in a month and a half. The NMPA has accepted the supplementary application for full product approval, expected to be approved in 1H25. Future sales growth will mainly come from the promotion and education of guidelines, and possible negotiations for medical insurance access; 2) Yijia sales amounted to 0.134 billion yuan (a 35% increase from 2H23), with subsequent growth prospects being the main focus.
No Data
No Data